Sophia G. Quesada
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sophia G. Quesada has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Muhammed A. Moukhtar Hammad
Department of Urology, University of California, Irvine , Orange, CA 92868
3 shared publications - Aimee L. Belczyk
Department of Urology, University of California Irvine, Orange, CA 92868, USA
2 shared publications - Gamal M. Ghoniem
Department of Urology, University of California Irvine, Orange, CA 92868, USA
2 shared publications - Elia Abou Chawareb
Department of Urology, University of California , Irvine, CA, 92868
1 shared publication Faysal A Yafi
Department of Urology, University of California , Irvine, CA, 92868
1 shared publicationHana S Nakamura
Department of Urology, University of California , Irvine, CA, 92868
1 shared publication
Latest Publications
- Open Access
- 2 July 2026
- Published by Oxford University Press (OUP) in Sexual Medicine
- Vol. 14 (5) , qfag050
Access without approval: state-level determinants of peptide availability in sexual medicine
Background: Despite increasing use of peptides in sexual medicine, interstate differences in access are not fully explained by federal approval status and may instead reflect variation in state-level healthcare delivery structures. Aim: To systematically compare state-level environments affecting access to peptide-based sexual medicine therapies using objective proxy measures and to generate a clinician-friendly framework for identifying geographic disparities. Methods: We conducted a cross-sectional, state-level analysis of all 50 U.S. states and the District of Columbia. Access environments were characterized using three reproducible proxy variables reflecting clinical feasibility of care: (1) telehealth prescribing permissiveness, (2) nurse practitioner (NP) practice authority, and (3) availability of FDA-registered 503B outsourcing facilities normalized by population. Each variable was coded on a standardized scale and averaged to generate a compositive Peptide Access Environment Score (PAES). States were stratified into high-, moderate-, and low-access tiers. Regional differences were evaluated using nonparametric statistical testing and geographic visualization. Outcomes: Primary outcomes included state-level PAES values and access tier classification. Secondary outcomes included regional variation and concordance between telehealth regulation and compounding infrastructure. Results: PAES values ranged from 0.33 to 1.56, demonstrating substantial interstate variability. High-access environments clustered predominantly in the Northeast and West, while low-access states were most frequently observed in the South and parts of the Midwest. Regional differences in PAES were statistically significant (p < .001). Discordance between telehealth prescribing permissiveness and compounding infrastructure was identified, with multiple states permitting telehealth initiation of care despite lacking in-state 503B facilities, and others possessing compounding capacity but maintaining restrictive telehealth regulations. Clinical implications: State-level healthcare delivery policies and infrastructure may meaningfully influence patient access to peptide-based sexual medicine therapies independent of peptide-specific regulatory status. Strengths and limitations: Strengths include a transparent, reproducible methodology using publicly available data and a clinically grounded, multidimensional access framework. Limitations include reliance on proxy measures, exclusion of physician assistant autonomy, and inability to assess within-state socioeconomic or urban–rural heterogeneity. Conclusion: Interstate differences in telemedicine permissiveness, NP practice authority, and compounding infrastructure are associated with significant geographic disparities in access to peptide-based sexual medicine therapies in the United States.
- 2 July 2026
- Published by Oxford University Press (OUP) in Sexual Medicine
- Vol. 14 (5) , qfag050
Open AccessAccess without approval: state-level determinants of peptide availability in sexual medicine
Background: Despite increasing use of peptides in sexual medicine, interstate differences in access are not fully explained by federal approval status and may instead reflect variation in state-level healthcare delivery structures. Aim: To systematically compare state-level environments affecting access to peptide-based sexual medicine therapies using objective proxy measures and to generate a clinician-friendly framework for identifying geographic disparities. Methods: We conducted a cross-sectional, state-level analysis of all 50 U.S. states and the District of Columbia. Access environments were characterized using three reproducible proxy variables reflecting clinical feasibility of care: (1) telehealth prescribing permissiveness, (2) nurse practitioner (NP) practice authority, and (3) availability of FDA-registered 503B outsourcing facilities normalized by population. Each variable was coded on a standardized scale and averaged to generate a compositive Peptide Access Environment Score (PAES). States were stratified into high-, moderate-, and low-access tiers. Regional differences were evaluated using nonparametric statistical testing and geographic visualization. Outcomes: Primary outcomes included state-level PAES values and access tier classification. Secondary outcomes included regional variation and concordance between telehealth regulation and compounding infrastructure. Results: PAES values ranged from 0.33 to 1.56, demonstrating substantial interstate variability. High-access environments clustered predominantly in the Northeast and West, while low-access states were most frequently observed in the South and parts of the Midwest. Regional differences in PAES were statistically significant (p < .001). Discordance between telehealth prescribing permissiveness and compounding infrastructure was identified, with multiple states permitting telehealth initiation of care despite lacking in-state 503B facilities, and others possessing compounding capacity but maintaining restrictive telehealth regulations. Clinical implications: State-level healthcare delivery policies and infrastructure may meaningfully influence patient access to peptide-based sexual medicine therapies independent of peptide-specific regulatory status. Strengths and limitations: Strengths include a transparent, reproducible methodology using publicly available data and a clinically grounded, multidimensional access framework. Limitations include reliance on proxy measures, exclusion of physician assistant autonomy, and inability to assess within-state socioeconomic or urban–rural heterogeneity. Conclusion: Interstate differences in telemedicine permissiveness, NP practice authority, and compounding infrastructure are associated with significant geographic disparities in access to peptide-based sexual medicine therapies in the United States.
- Open Access
Beyond Glycemic Control: Concurrent GLP-1 Receptor Agonist Use Is Associated with Reduced Urinary Adverse Events Following OnabotulinumtoxinA Treatment in Non-Diabetic Adults with Overactive Bladder
Semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist, is widely prescribed for weight loss in non-diabetic populations. Given the link between obesity and overactive bladder (OAB), we explored whether GLP-1 use would improve adverse urinary events beyond its weight loss benefit for non-diabetic adults undergoing onabotulinumtoxin A (BTX-A) treatment for OAB. Using the TriNetX database, we conducted a retrospective cohort study of non-diabetic OAB patients treated with BTX-A alone or with concurrent GLP-1 therapy. Propensity score matching (1:1) was adjusted for age, race, ethnicity, hypertension, and BMI/obesity. After matching, 992 patients were included in each group. GLP-1 use was associated with a lower incidence of urinary retention (8.6% vs. 4.9%, risk difference 3.66%, p = 0.0044) and urinary tract infection (13.3% vs. 8.8%, risk difference 4.54%, p = 0.00224), with corresponding improved one-year retention-free and UTI-free survival on Kaplan–Meier (KM) analysis. Antispasmodic initiation rates were similar (11.8% vs. 10.3%, risk difference 1.55%, p = 0.6921), and KM analysis showed no significant difference. These findings suggest that GLP-1 receptor agonist use may improve select urinary adverse events in non-diabetic adults undergoing BTX-A treatment for OAB and support further investigation into its potential adjunctive role in OAB management with longer follow-up.
Open AccessBeyond Glycemic Control: Concurrent GLP-1 Receptor Agonist Use Is Associated with Reduced Urinary Adverse Events Following OnabotulinumtoxinA Treatment in Non-Diabetic Adults with Overactive Bladder
Semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist, is widely prescribed for weight loss in non-diabetic populations. Given the link between obesity and overactive bladder (OAB), we explored whether GLP-1 use would improve adverse urinary events beyond its weight loss benefit for non-diabetic adults undergoing onabotulinumtoxin A (BTX-A) treatment for OAB. Using the TriNetX database, we conducted a retrospective cohort study of non-diabetic OAB patients treated with BTX-A alone or with concurrent GLP-1 therapy. Propensity score matching (1:1) was adjusted for age, race, ethnicity, hypertension, and BMI/obesity. After matching, 992 patients were included in each group. GLP-1 use was associated with a lower incidence of urinary retention (8.6% vs. 4.9%, risk difference 3.66%, p = 0.0044) and urinary tract infection (13.3% vs. 8.8%, risk difference 4.54%, p = 0.00224), with corresponding improved one-year retention-free and UTI-free survival on Kaplan–Meier (KM) analysis. Antispasmodic initiation rates were similar (11.8% vs. 10.3%, risk difference 1.55%, p = 0.6921), and KM analysis showed no significant difference. These findings suggest that GLP-1 receptor agonist use may improve select urinary adverse events in non-diabetic adults undergoing BTX-A treatment for OAB and support further investigation into its potential adjunctive role in OAB management with longer follow-up.
- Open Access
- 7 August 2025
- Published by MDPI AG in Preprints.org
Beyond Glycemic Control: Semaglutide Use in Non-Diabetic Female Patients with Overactive Bladder Receiving BOTOX is Associated with Improved Urinary Outcome
Semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist, is widely prescribed for weight loss in non-diabetic populations. Given the link between obesity and over-active bladder (OAB), we explored whether GLP-1 use would improve urinary out-comes beyond its weight loss benefit for non-diabetic adults undergoing BOTOX treatment for OAB. Using the TriNetX database, we conducted a retrospective cohort study of non-diabetic OAB patients treated with BOTOX alone or with concurrent GLP-1 therapy. Propensity score matching (1:1) adjusted for age, race, ethnicity, hypertension, and BMI/obesity. After matching, 992 patients were included in each group. GLP-1 use was associated with a lower incidence of urinary retention (8.6% vs. 4.9%, risk difference 3.66%, p = 0.0044) and urinary tract infection (13.3% vs. 8.8%, risk difference 4.54%, p = 0.00224), with corresponding improved one-year retention-free and UTI-free survival on Kaplan Meier (KM) analysis. Antispasmodic initiation rates were similar (11.8% vs. 10.3%, risk difference 1.55%, p = 0.6921), and KM analysis showed no significant difference. These findings suggest that GLP-1 receptor agonist use may improve select urinary outcomes in non-diabetic adults undergoing BOTOX treatment for OAB and support further investigation into its potential adjunctive role in OAB management with longer follow-up.
- 7 August 2025
- Published by MDPI AG in Preprints.org
Open AccessBeyond Glycemic Control: Semaglutide Use in Non-Diabetic Female Patients with Overactive Bladder Receiving BOTOX is Associated with Improved Urinary Outcome
Semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist, is widely prescribed for weight loss in non-diabetic populations. Given the link between obesity and over-active bladder (OAB), we explored whether GLP-1 use would improve urinary out-comes beyond its weight loss benefit for non-diabetic adults undergoing BOTOX treatment for OAB. Using the TriNetX database, we conducted a retrospective cohort study of non-diabetic OAB patients treated with BOTOX alone or with concurrent GLP-1 therapy. Propensity score matching (1:1) adjusted for age, race, ethnicity, hypertension, and BMI/obesity. After matching, 992 patients were included in each group. GLP-1 use was associated with a lower incidence of urinary retention (8.6% vs. 4.9%, risk difference 3.66%, p = 0.0044) and urinary tract infection (13.3% vs. 8.8%, risk difference 4.54%, p = 0.00224), with corresponding improved one-year retention-free and UTI-free survival on Kaplan Meier (KM) analysis. Antispasmodic initiation rates were similar (11.8% vs. 10.3%, risk difference 1.55%, p = 0.6921), and KM analysis showed no significant difference. These findings suggest that GLP-1 receptor agonist use may improve select urinary outcomes in non-diabetic adults undergoing BOTOX treatment for OAB and support further investigation into its potential adjunctive role in OAB management with longer follow-up.